Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases

Richard J Cote, Paul P. Rosen, Martin L. Lesser, Lloyd J. Old, Michael P. Osborne

Research output: Contribution to journalArticle

419 Citations (Scopus)

Abstract

We used monoclonal antibodies to identify occult micrometastases in the bone marrow of 49 patients with operable (stage I and II) breast carcinoma. Follow-up (mean, 29 months; median, 30 months) revealed that 12 patients recurred. The presence of bone marrow micrometastases (BMM) was significantly associated with early recurrence (P < .04). The estimated 2-year recurrence rate for patients with no BMM detected (BMM-) was 3%; in patients with BMM, the 2-year recurrence rate was 33%. When BMM and axillary lymph node (LN) status were combined, groups of patients at low risk (LN-, BMM-; 2-year recurrence rate, 0%) and high risk (LN+ , BMM+; 2-year recurrence rate, 42%) for early recurrence were identified. Bone marrow tumor burden was related to early recurrence. Among patients with BMM, those who did not recur had on average fewer extrinsic cells in their marrow than those who recurred (15 v 43 cells, respectively). Multivariate analysis comparing BMM, LN+ versus LN-, and tumor size (≤ 2 cm v > 2 cm) revealed no factor independently associated with early recurrence. Peripheral tumor burden of BMM (0 or < 10 extrinsic cells v ≥ 10 extrinsic cells) was the only independent predictor of early recurrence (P < .003). In conjunction with conventional prognostic factors, particularly axillary LN status, evaluation for BMM might be used to stratify patients for adjuvant treatment programs. Because this pilot study involved few patients with short-term follow-up, the results should be interpreted with caution. The examination of bone marrow for micrometastases remains an experimental procedure; the clinical usefulness of the test will be established through larger studies with long-term follow-up.

Original languageEnglish
Pages (from-to)1749-1756
Number of pages8
JournalJournal of Clinical Oncology
Volume9
Issue number10
StatePublished - Oct 1 1991
Externally publishedYes

Fingerprint

Neoplasm Micrometastasis
Bone Marrow
Breast Neoplasms
Recurrence
Bone Marrow Examination
Tumor Burden
Monoclonal Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. / Cote, Richard J; Rosen, Paul P.; Lesser, Martin L.; Old, Lloyd J.; Osborne, Michael P.

In: Journal of Clinical Oncology, Vol. 9, No. 10, 01.10.1991, p. 1749-1756.

Research output: Contribution to journalArticle

Cote, Richard J ; Rosen, Paul P. ; Lesser, Martin L. ; Old, Lloyd J. ; Osborne, Michael P. / Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. In: Journal of Clinical Oncology. 1991 ; Vol. 9, No. 10. pp. 1749-1756.
@article{1f2a0f00332b463181984382245fb1df,
title = "Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases",
abstract = "We used monoclonal antibodies to identify occult micrometastases in the bone marrow of 49 patients with operable (stage I and II) breast carcinoma. Follow-up (mean, 29 months; median, 30 months) revealed that 12 patients recurred. The presence of bone marrow micrometastases (BMM) was significantly associated with early recurrence (P < .04). The estimated 2-year recurrence rate for patients with no BMM detected (BMM-) was 3{\%}; in patients with BMM, the 2-year recurrence rate was 33{\%}. When BMM and axillary lymph node (LN) status were combined, groups of patients at low risk (LN-, BMM-; 2-year recurrence rate, 0{\%}) and high risk (LN+ , BMM+; 2-year recurrence rate, 42{\%}) for early recurrence were identified. Bone marrow tumor burden was related to early recurrence. Among patients with BMM, those who did not recur had on average fewer extrinsic cells in their marrow than those who recurred (15 v 43 cells, respectively). Multivariate analysis comparing BMM, LN+ versus LN-, and tumor size (≤ 2 cm v > 2 cm) revealed no factor independently associated with early recurrence. Peripheral tumor burden of BMM (0 or < 10 extrinsic cells v ≥ 10 extrinsic cells) was the only independent predictor of early recurrence (P < .003). In conjunction with conventional prognostic factors, particularly axillary LN status, evaluation for BMM might be used to stratify patients for adjuvant treatment programs. Because this pilot study involved few patients with short-term follow-up, the results should be interpreted with caution. The examination of bone marrow for micrometastases remains an experimental procedure; the clinical usefulness of the test will be established through larger studies with long-term follow-up.",
author = "Cote, {Richard J} and Rosen, {Paul P.} and Lesser, {Martin L.} and Old, {Lloyd J.} and Osborne, {Michael P.}",
year = "1991",
month = "10",
day = "1",
language = "English",
volume = "9",
pages = "1749--1756",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases

AU - Cote, Richard J

AU - Rosen, Paul P.

AU - Lesser, Martin L.

AU - Old, Lloyd J.

AU - Osborne, Michael P.

PY - 1991/10/1

Y1 - 1991/10/1

N2 - We used monoclonal antibodies to identify occult micrometastases in the bone marrow of 49 patients with operable (stage I and II) breast carcinoma. Follow-up (mean, 29 months; median, 30 months) revealed that 12 patients recurred. The presence of bone marrow micrometastases (BMM) was significantly associated with early recurrence (P < .04). The estimated 2-year recurrence rate for patients with no BMM detected (BMM-) was 3%; in patients with BMM, the 2-year recurrence rate was 33%. When BMM and axillary lymph node (LN) status were combined, groups of patients at low risk (LN-, BMM-; 2-year recurrence rate, 0%) and high risk (LN+ , BMM+; 2-year recurrence rate, 42%) for early recurrence were identified. Bone marrow tumor burden was related to early recurrence. Among patients with BMM, those who did not recur had on average fewer extrinsic cells in their marrow than those who recurred (15 v 43 cells, respectively). Multivariate analysis comparing BMM, LN+ versus LN-, and tumor size (≤ 2 cm v > 2 cm) revealed no factor independently associated with early recurrence. Peripheral tumor burden of BMM (0 or < 10 extrinsic cells v ≥ 10 extrinsic cells) was the only independent predictor of early recurrence (P < .003). In conjunction with conventional prognostic factors, particularly axillary LN status, evaluation for BMM might be used to stratify patients for adjuvant treatment programs. Because this pilot study involved few patients with short-term follow-up, the results should be interpreted with caution. The examination of bone marrow for micrometastases remains an experimental procedure; the clinical usefulness of the test will be established through larger studies with long-term follow-up.

AB - We used monoclonal antibodies to identify occult micrometastases in the bone marrow of 49 patients with operable (stage I and II) breast carcinoma. Follow-up (mean, 29 months; median, 30 months) revealed that 12 patients recurred. The presence of bone marrow micrometastases (BMM) was significantly associated with early recurrence (P < .04). The estimated 2-year recurrence rate for patients with no BMM detected (BMM-) was 3%; in patients with BMM, the 2-year recurrence rate was 33%. When BMM and axillary lymph node (LN) status were combined, groups of patients at low risk (LN-, BMM-; 2-year recurrence rate, 0%) and high risk (LN+ , BMM+; 2-year recurrence rate, 42%) for early recurrence were identified. Bone marrow tumor burden was related to early recurrence. Among patients with BMM, those who did not recur had on average fewer extrinsic cells in their marrow than those who recurred (15 v 43 cells, respectively). Multivariate analysis comparing BMM, LN+ versus LN-, and tumor size (≤ 2 cm v > 2 cm) revealed no factor independently associated with early recurrence. Peripheral tumor burden of BMM (0 or < 10 extrinsic cells v ≥ 10 extrinsic cells) was the only independent predictor of early recurrence (P < .003). In conjunction with conventional prognostic factors, particularly axillary LN status, evaluation for BMM might be used to stratify patients for adjuvant treatment programs. Because this pilot study involved few patients with short-term follow-up, the results should be interpreted with caution. The examination of bone marrow for micrometastases remains an experimental procedure; the clinical usefulness of the test will be established through larger studies with long-term follow-up.

UR - http://www.scopus.com/inward/record.url?scp=0026003325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026003325&partnerID=8YFLogxK

M3 - Article

C2 - 1919627

AN - SCOPUS:0026003325

VL - 9

SP - 1749

EP - 1756

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -